CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 280 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $127,090,442 | -16.7% | 2,353,091 | +5.1% | 0.01% | -20.0% |
Q1 2024 | $152,656,804 | +32.5% | 2,239,683 | +21.7% | 0.01% | +11.1% |
Q4 2023 | $115,175,906 | +23.3% | 1,839,871 | -10.6% | 0.01% | +12.5% |
Q3 2023 | $93,386,022 | -20.5% | 2,057,414 | -1.6% | 0.01% | -20.0% |
Q2 2023 | $117,398,452 | -39.3% | 2,091,173 | -51.1% | 0.01% | +11.1% |
Q1 2023 | $193,499,006 | +117.9% | 4,278,112 | +95.8% | 0.01% | 0.0% |
Q4 2022 | $88,795,210 | -36.7% | 2,184,384 | +1.8% | 0.01% | -40.0% |
Q3 2022 | $140,270,000 | +42.6% | 2,146,444 | +32.6% | 0.02% | +50.0% |
Q2 2022 | $98,388,000 | +24.2% | 1,619,022 | +28.3% | 0.01% | +66.7% |
Q1 2022 | $79,192,000 | +181.9% | 1,261,622 | +240.3% | 0.01% | +200.0% |
Q4 2021 | $28,093,000 | -56.3% | 370,722 | -35.5% | 0.00% | -60.0% |
Q3 2021 | $64,302,000 | -31.1% | 574,481 | -0.4% | 0.01% | -28.6% |
Q2 2021 | $93,367,000 | +34.9% | 576,727 | +1.6% | 0.01% | +16.7% |
Q1 2021 | $69,201,000 | -50.2% | 567,922 | -37.4% | 0.01% | -50.0% |
Q4 2020 | $138,992,000 | +75.2% | 907,789 | -4.3% | 0.01% | +50.0% |
Q3 2020 | $79,328,000 | +3.6% | 948,453 | -9.0% | 0.01% | 0.0% |
Q2 2020 | $76,563,000 | +105.8% | 1,041,810 | +18.8% | 0.01% | +60.0% |
Q1 2020 | $37,194,000 | -35.9% | 877,014 | -7.9% | 0.01% | -16.7% |
Q4 2019 | $58,004,000 | +155.3% | 952,369 | +71.8% | 0.01% | +100.0% |
Q3 2019 | $22,723,000 | +61.8% | 554,357 | +85.9% | 0.00% | +50.0% |
Q2 2019 | $14,048,000 | +62.3% | 298,269 | +23.1% | 0.00% | +100.0% |
Q1 2019 | $8,656,000 | -4.1% | 242,336 | -23.3% | 0.00% | 0.0% |
Q4 2018 | $9,024,000 | -31.9% | 315,836 | +5.7% | 0.00% | 0.0% |
Q3 2018 | $13,257,000 | +14.0% | 298,936 | +51.0% | 0.00% | 0.0% |
Q2 2018 | $11,629,000 | – | 197,908 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |